Navigation Links
BioMarin Announces First Quarter 2008 Financial Results
Date:4/29/2008


First Quarter Profit Driven by Strong Revenue Growth Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)

Financial Highlights

Item Q1 2008 (millions) Q1 2007 Comparison

Total BioMarin Revenue $60.4 164.5% increase

Naglazyme Net Product Revenue $27.7 50.5% increase

Aldurazyme (net sales by Genzyme) $36.8 37.3% increase

Aldurazyme (revenue to BioMarin) $24.1 NA

Kuvan Net Product Revenue $5.8 NA

GAAP Net Income (loss) $1.7, $0.02 ($9.3),($0.10)

per share per share

Non-GAAP Net Income (loss) $6.2, $0.06 ($5.7), ($0.06)

per share per share

2008 Guidance

Item Updated Guidance Previous Guidance

(millions) (millions)

Total BioMarin Revenue $271 to $316 $255 to $306

Total Product Revenue $230 to $275 $213 to $264

Naglazyme Net Product Revenue $115 to $125 $105 to $116

Aldurazyme Net Product Sales

by Genzyme Unchanged $135 to $145

Aldurazyme Net Product Revenue

to BioMarin $70 to $80 $68 to $78

Kuvan Net Product Revenue $45 to $70 $40 to $70

Net Income (GAAP)* $28 to $40 $20 to $40

Net Income (non-GAAP)* $52 to $67 $47 to $67

* Assumes that the $30 million milestone for EU Kuvan approval will be

earned in 2008

NOVATO, Calif., April 29 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMarin to Present at the Morgan Stanley Healthcare Conference
2. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
3. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
4. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
5. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
6. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
7. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
8. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
9. BioMarin to Present at the BioCentury NewsMakers Conference
10. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
11. Align Technology Announces $50 Million Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... Biotech Product with ... Direct Consumer Benefits, DES MOINES, Iowa, ... oil trait from DuPont (NYSE: DD ),will deliver increased nutritional ... market. The high oleic soybean,oil trait is the next generation of ...
... Data presented at AAAAI 64th Annual Meeting also show ... effective treatment for HAE attacks across all body sites, ... a safe and effective therapy that rapidly relieves acute,abdominal ... a rare and serious genetic disorder, according to data,presented ...
... March 18 /PRNewswire/ - Aegera Therapeutics announced ... clinical trial for AEG33773, a,novel, orally bioavailable ... painful diabetic neuropathy. The Phase I study ... of AEG33773 using a randomized,double blind, placebo ...
Cached Biology Technology:Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 2Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2
(Date:8/22/2014)... (Maximizing Access to Research Careers) Program has announced the ... & Practical Exercises Workshop which will be held on ... 25-26, 2014. These awards are meant to help ... underrepresented groups in the the FASEB Grant Writing Seminar ... 11 awards totaling $20,350. , The FASEB MARC Program ...
(Date:8/22/2014)... can probably remember the after-effects, including pain, swelling or ... back against the injury. When tissue in the body ... tissue regeneration. An inflammatory response acts as a protective ... to heal after injuries such as wounds and burns. ... situations in which foreign material is introduced, for example ...
(Date:8/22/2014)... important discoveries in basic and clinical research and ... into a complex offensive spanning multiple fronts. , ... lab could help find new and more selective ... that targets a specific enzyme overexpressed in certain ... from brain tumours. , Chemistry professor Christopher Cairo ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... Using an extremely sensitive measurement technique, researchers at ... a lead-specific DNAzyme uses the lock and key reaction ... the same DNAzyme uses the induced fit reaction ... and key mechanism explains why this particular lead-specific DNAzyme ...
... Molecular Biology Laboratory [EMBL] announces Luxembourg as the ... EMBL,s council and ratified by the parliament of ... as the 20th member state. "EMBL is ... Franois Biltgen, Minister of Culture, Higher Education and ...
... researchers have engineered with a novel inkjet printing method ... harmful industrial solvents and explosives. Led by MIT ... to print thin sensor films onto a microchip, a ... highly sensitive gas detectors. Mass production would ...
Cached Biology News:The key to unlocking the secret of highly specific DNAzyme catalysis 2Luxembourg joins EMBL 2MIT's 'electronic nose' could detect hazards 2MIT's 'electronic nose' could detect hazards 3
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
... for spontaneous ligand immobilization can be coupled with ... or receptor to create an affinity matrix of ... ligands via primary amines. Affi-Gel 10 gel couples ... to 11; Affi-Gel 15 gel couples acidic proteins ...
Biology Products: